|
Abraxis BioScience Receives FDA Approval for Caffeine Citrate Injection USP, 20 mg/mL |
|
|
|
04 Aug 2007 |
Abraxis BioScience, Inc. an integrated, global biopharmaceutical company, announced that its hospital-based products business, Abraxis Pharmaceutical Products, has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Caffeine Citrate injection, USP, 20 mg/mL, the generic equivalent of Cafcit(R) Injection manufactured by Mead Johnson and Company
LOS ANGELES, CA, USA | August 2, 2007 | Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today announced that its hospital-based products business, Abraxis Pharmaceutical Products (APP), has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Caffeine Citrate injection, USP, 20 mg/mL, the generic equivalent of Cafcit(R) Injection manufactured by Mead Johnson and Company. According to IMS data, annual sales in 2006 of this product across all distributors and dosage forms were approximately $16 million. APP will package this product in 60 mg/3mL single-use vials and expects to commence marketing of this product immediately.
Caffeine Citrate Injection is indicated for the short term treatment of apnea of prematurity (AOP) in infants between 28 and <33 weeks gestational age. AOP is a condition in which cessation of breathing in pre-term infants can cause dangerously low levels of blood oxygen.
APP manufactures and markets one of the most comprehensive injectable portfolios of products to the U.S. hospital-based market. The current injectable portfolio is comprised of anti-infectives, critical care, oncology and anesthetic/analgesic products totaling over 400 dosage forms. Including those ANDAs pending with the FDA, APP currently has over 60 product candidates in various stages of development.
About Abraxis BioScience, Inc.
Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this nab platform, ABRAXANE(R), was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the Nasdaq Global Market under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com.
SOURCE: ABRAXIS BIOSCIENCE, INC. |
